Table 1 Characteristics of the included studies
Author (study period) | Nation | Study design | No. of patients | Histology | Clinical stage | Neoadjuvant chemoradiotherapy (nCRT) | Work-up after nCRT | Outcome (2Â yr-OS (%)/2Â yr-DFS (%)) | Quality assessmentb |
|---|---|---|---|---|---|---|---|---|---|
Castro [15] (1992–2007) | Italy | Retrospective | nCRT (n = 38) | SCC only | II–IV | nCRT 45–50 Gy in 1.8 Gy daily fraction with FP | Endoscopy with biopsies, CT | 72.2/39.8 | Moderate |
nCRT + S (n = 39) | 72.2/64.8 | ||||||||
Chao [16] (1996–2006) | Taiwan | Retrospective | nCRT (n = 79) | SCC only | II–IVa | Induction FP#1 + nCRT 30 Gy/15 fx with FP boost 30 Gy/15fx (pT3 or pN + in in surgery or in without surgery) | Endoscopy with biopsies, CT | 62.8 | Moderate |
nCRT + S (n = 71) | 56.1 | ||||||||
Piessen [17] (1995–2012) | France | Retrospective | nCRT (n = 59) | SCC (n = 149) | II–III | nCRT 45 Gy/25 fx with FP | Endoscopy with biopsies, barium swallow, CT (PET was used selectively.) | 58.0/58.2 | High |
nCRT + S (n = 118) | ADC (n = 28) | 81.0*/80.4* | |||||||
Jeong [14] (2005–2008) | Korea | Retrospective | nCRT (n = 31) | SCC only | II–IVa | Induction XP#2 + nCRT with XP | Endoscopy with or without biopsy, EUS, CT, PET | 61.3/47.3 | Moderate |
nCRT + S (n = 39) | nCRT + S: 46 Gy/23 fx | 71.8/83.0* | |||||||
nCRT: 54Â Gy/27 fx | |||||||||
Wilk [18] (2013–2016) | Netherland | Retrospective | nCRT (n = 29) | SCC (n = 26) | II–III | nCRT 41.4 Gy/23 fx with PC | Endoscopy with biopsies (bite-on-bite), EUS, PET | 89.7/73.5 | High |
ADC (n = 71) | |||||||||
ADSC (n = 1) | |||||||||
nCRT + S (n = 29) | 69.0/76.3 | ||||||||
Park [12] (2012–2016) | Korea | Prospective | nCRT (n = 18) | SCC only | II–III | Induction XP#2 + nCRT with XP | Endoscopy with or without biopsy, EUS, CT, PET | 72.8/42.7 | Moderate |
nCRT + S (n = 19) | 50.4 Gy/28 fx with XP | 74.4/66.7 |